Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient.
Hartinger
C G
CG
Institute of Inorganic Chemistry - Bioinorganic, Environmental and Radiochemistry, University of Vienna, Austria.
Hann
S
S
Koellensperger
G
G
Sulyok
M
M
Groessl
M
M
Timerbaev
A R
AR
Rudnev
A V
AV
Stingeder
G
G
Keppler
B K
BK
D000418:Albumins / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D019075:Electrophoresis, Capillary; D006801:Humans; D007191:Indazoles / Q000378:metabolism*; D009369:Neoplasms / Q000097:blood / Q000378:metabolism*; D009942:Organometallic Compounds; D011485:Protein Binding; D012428:Ruthenium; D017975:Ruthenium Compounds / Q000378:metabolism*; D021241:Spectrometry, Mass, Electrospray Ionization; D014168:Transferrin / Q000378:metabolism*
D000418:Albumins; D000970:Antineoplastic Agents; D007191:Indazoles; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D014168:Transferrin; C499292:indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III)); D012428:Ruthenium